XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands):
Years ended December 31,
20212020            2019
Stock options$2,480 $1,763 $688 
Restricted stock awards4,265 1,620 252 
APC stock options— — 607 
Total share-based compensation expense$6,745 $3,383 $1,547 
Schedule of Stock Option Transactions Under Stock Option Plans The Company’s outstanding stock options consisted of the following:
SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2021725,864 $13.25 3.75$3.4 
Options granted137,927 66.29 — — 
Options exercised(40,000)5.20 — 2.8 
Options canceled, forfeited or expired(9,826)3.89 — — 
Options outstanding at December 31, 2021813,965 $22.74 3.20$41.6 
Options exercisable at December 31, 2021618,006 $10.22 2.14$37.1 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
During the year ended December 31, 2021, the Company granted 0.1 million five-year stock options to certain ApolloMed executives with exercise price ranging from $23.24-$80.00. The weighted-average grant-date fair value of options granted during the years ended December 31, 2021, 2020, and 2019 was $32.63, $9.89, and $11.33, respectively. The options granted during the year ended December 31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
December 31, 2021Executives
Expected term3.5 years
Expected volatility
75.45% - 81.10%
Risk-free interest rate
0.19% - 1.15%
Market value of common stock
12.86-37.82
Annual dividend yield0 %
Forfeiture rate0 %
Share-based Payment Arrangement, Restricted Stock Activity The Company’s unvested restricted stock award activity for the year ended December 31, 2021 consisted of the following:
Number of
Shares		Weighted Average
Grant-Date Fair Value
Unvested as of January 1, 2021262,419$17.96
Granted 332,20250.73
Vested(39,910)17.03
Forfeited(13,204)29.88
Unvested as of December 31, 2021541,507$37.84
Schedule of Warrants Outstanding
The Company’s outstanding warrants consisted of the following:
SharesWeighted-Average
Exercise
Price		Weighted-Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
(in millions)
Warrants outstanding at January 1, 20211,878,126 $10.39 1.6314.8 
Warrants granted— — — — 
Warrants exercised(858,583)10.30 — 41.1 
Warrants forfeited(17,803)9.72 — — 
Warrants outstanding at December 31, 20211,001,740 $10.49 0.94$63.1 
Exercise Price Per
Share		Warrants
Outstanding		Weighted-
Average
Remaining
Contractual Life		Warrants
Exercisable		Weighted-
Average
Exercise Price
Per
Share
10.00 515,176 0.94515,176 10.00 
11.00 486,564 0.94486,564 11.00 
$10.00 – $11.00
1,001,740 0.941,001,740 $10.49